About Gruenenthal Group
Gruenenthal Group is a Healthcare company based in Aachen (Germany) founded in 1946. Specialty biopharmaceutical products are developed internationally by Gruenenthal Group. Gruenenthal Group has completed 8 acquisitions, including Adhesys Medical, AstraZeneca and Averitas Pharma. Its website grunenthal.com draws about 37 thousand monthly visits. Gruenenthal Group offers products and services including RTX and Pain Management Solutions. Its focus areas include Diversified Pharmaceuticals. Its legal entity is GRUNENTHAL USA, INC.
Company details
Gruenenthal Group was founded in 1946 as an independent, family-owned entity based in Aachen, Germany. Operations focus on the biopharmaceutical sector, with products addressing pain, inflammation, movement and bone disorders, perioperative care, neurology, cancer supportive care, CNS conditions, and womens health. International expansion has been achieved through acquisitions, including Mexicos Almirall in March 2016 and the U.S.-based Thar Pharmaceuticals in November 2016.
- Latest Funding Round$543.79M (USD), Debt – Conventional
Mar 2023
- Investors
- Investments & AcquisitionsAdhesys Medical
& 7 more
Products & Services of Gruenenthal Group
Gruenenthal Group offers a comprehensive portfolio of products and services, including RTX and Pain Management Solutions.
Treatment for severe pain conditions like neuropathic pain
Medicines for chronic post-surgical and low back pain
Apps and channels of Gruenenthal Group
its YouTube channel Grunenthal Health has 1.81K subscribers and 30 videos.
Videos from Gruenenthal Group
The most watched videos on Gruenenthal Group's YouTube channel, Grunenthal Health (1.81K subscribers). Click a video to play it here.
More on Grunenthal Health.
Funding Insights of Gruenenthal Group
- Total Rounds 3
- Last Round Debt – Conventional — $543.79M
- First Round $301,268
(Jan 2015)
- Investors Count 1
All 3 funding rounds of Gruenenthal Group with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $543.79M | Debt – Conventional | – | – | – |
| Sep 2016 | $1.69M | Grant | – | – | |
| Jan 2015 | $301,268 | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in Gruenenthal Group
Gruenenthal Group has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Commission.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium |
Investor details for Gruenenthal Group
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Gruenenthal Group
283 people are tracked at Gruenenthal Group (124 in leadership, 5 in board & advisors, 154 in team).
| Name | Role | Group |
|---|---|---|
Chanchal Kumar | Head Bioinformatics And Disease Understanding | Leadership |
Uli Brödl | Head of R&D, CSO & Member of the Corporate Executive Board | Leadership |
Andy Mead | Senior Director, Head Of Toxicology | Leadership |
Dalena Brockwell | Head, Regulatory Affairs - North America | Leadership |
Gabriel Baertschi | CEO | Leadership |
Jan Adams | Chief Commercial Officer | Leadership |
Keith Phillips | Vice President, Head Of Novel Therapeutic Modalities | Leadership |
Mark Uyterwijk | Director / Teamlead Category Management | Leadership |
Wojciech Sulimierski | Senior Director, Area Management Europe-partner Business, GBD | Leadership |
Bianca Neumair | Head Of Global Legal Operations | Leadership |
Florian Dehmel | Head Of Global Patents & Trademarks | Leadership |
Daniela Hellenbrandt | Assistant – Head Of Marketing & Omnichannel Delivery | Leadership |
Mubasher Hassan | Global Head Of Content Management | Leadership |
Pavithra Sundaresan | Vp, Head Of External Innovation | Leadership |
Funso Olufade | Head, Finance & Controlling - US | Leadership |
Leen Hofkens | Head, Global HR | Leadership |
Quentin Le Masne de Chermont | Head, Corporate Strategy | Leadership |
Fabian Raschke | Chief Financial Officer | Leadership |
Maximilian von Eynatten | Head Of Development | Leadership |
Dr. Klemens Schulz | Director Commercial Development | Leadership |
263 more people are available in the full profile.
Complete people profiles for Gruenenthal Group
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gruenenthal Group
Gruenenthal Group has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Adhesys Medical, AstraZeneca and Averitas Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
A medicine for pain management is developed by the company. | valinorrx.com | Chicago, United States | 2021 | Jul 2024 | •••• | |
Prescription medicine for treating constipation caused by opioid pain medicines | movantik.com | 2013 | Jul 2024 | •••• | ||
Standalone men health clinic | nebido.com | Berlin, Germany | 2002 | Jul 2022 | •••• | |
Therapy for osteoarthritis-related joint pain is developed. | mestex.ch | Basel, Switzerland | 2014 | Apr 2021 | •••• | |
Manufacturer of non-opioid drugs | averitaspharma.com | Morristown, United States | 2018 | Nov 2018 | •••• | |
Manufacturer of bio-degradable polyurethane-based surgical sealants | adhesys-medical.com | Aachen, Germany | 2013 | Apr 2017 | •••• | |
Website providing information about prescription medicine for DPN and PHN | qutenza.com | Morristown, United States | 2007 | Dec 2016 | •••• | |
Improvement and optimization of Drug | tharpharma.com | Pittsburgh, United States | 2008 | Nov 2016 | •••• |
Complete acquisition details for Gruenenthal Group
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Gruenenthal Group
11 dated milestones of Gruenenthal Group across 78 years, from founding to its latest funding, stage changes and deals.
- Founded Gruenenthal Group is founded.
- Funding First funding round of $301K.
- Acquisition Acquires Thar Pharma.
- Acquisition Acquires QUTENZA.
- Acquisition Acquires Adhesys Medical.
- Acquisition Acquires Averitas Pharma.
- Acquisition Acquires Mestex.
- Acquisition Acquires Nebido.
- Funding Latest funding round, Debt – Conventional, of $543.8M.
- Acquisition Acquires Valinor Pharma.
- Acquisition Acquires AstraZeneca.
Web traffic of Gruenenthal Group
The website of Gruenenthal Group (grunenthal.com) receives about 37.5K visits a month and ranks #834,989 among all websites worldwide, #999 in Biotechnology and Pharmaceuticals.
- Monthly visits37.5K
▲ 10.1% vs previous month
- Unique visitors15.2K
per month
- Global rank#834,989
among all websites
- Category rank#999
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.2
- Average visit27 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Gruenenthal Group. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
| amgen.com | 100% | 495.4K | #116,434 | View details | |
| pierre-fabre.com | 83% | 125.2K | #237,153 | View details | |
astellas.us | astellas.us | 83% | #2,059,035 | – | |
novartis.ru | novartis.ru | 83% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 36 similar websites and full traffic analytics for Gruenenthal Group
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 36 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gruenenthal Group
Complete news archive for Gruenenthal Group
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gruenenthal Group
Gruenenthal Group was founded in 1946 and raised its 1st funding round 69 years after it was founded.
Gruenenthal Group is headquartered in Aachen, Germany. It is registered at Aachen, North Rhine-westphalia, Germany.
Gruenenthal Group was founded in 1946 as an independent, family-owned entity based in Aachen, Germany. Operations focus on the biopharmaceutical sector, with products addressing pain, inflammation, movement and bone disorders, perioperative care, neurology, cancer supportive care, CNS conditions, and womens health. International expansion has been achieved through acquisitions, including Mexicos Almirall in March 2016 and the U.S.-based Thar Pharmaceuticals in November 2016.
Gruenenthal Group offers RTX and Pain Management Solutions.
Gruenenthal Group has made 8 acquisitions, including Adhesys Medical, AstraZeneca, and Averitas Pharma.
Gruenenthal Group has 1 investor. Key investors include European Commission.
Gruenenthal Group operates through Grunenthal Usa, Inc..